Best Drug Delivery Companies in England, United Kingdom
The 48 best Drug Delivery companies in England, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Oxular.
Ranked: Best Drug Delivery companies in England
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Oxular Developer of drug delivery platform and therapeutics for ophthalmology | $58M | 65 mo ago | 6 | — | — | — | 79 patents Formulation and delivery systems for ocular therapeutics | — |
| 2 | ViaNautis Developer of targeted nanomedicines for drug delivery | $25M | 33 mo ago | — | Francesca Crawford Co-Founder & CEO | WordPressMySQLPHP+14 | Top 10M | — | — |
| 3 | Blueberry Therapeutics Developer of OTC and prescription products to treat infectious and inflammatory diseases | $24M | 62 mo ago | 15 | Michael Davies Co-Founder | — | — | 58 patents Antifungal topical pharmaceutical compositions and delivery methods for skin infections. | — |
| 4 | NanoSyrinx Developer of targeted intracellular delivery platform for biological molecules | $22M | 23 mo ago | 3 | Nick Waterfield Co-Founder | WordPressMySQLPHP+20 | Top 50M | — | — |
| 5 | Midatech Provider of novel drug delivery technologies for the treatment of diseases | $16M | 42 mo ago | 40 40 → 24 (-40%) | — | — | — | 204 patents Cyclodextrin and nanoparticle-based drug delivery systems for oncology and immunotherapy | 1 job opening · 1 expansion |
| 6 | Medherant Transdermal drug delivery patches | $13M | 40 mo ago | 18 18 → 16 (-11%) | David Haddleton Founder | WordPress Block EditorWordPressMySQL+17 | Top 50M | 43 patents Transdermal drug delivery patches and associated skin‑penetration formulations | — |
| 7 | Sixfold Bioscience Developer of oligonucleotide delivery systems | $10M | 56 mo ago | 16 | — | Webflowcore-jsjQuery+6 | Top 50M | 25 patents Nucleic‑acid nanoparticle platforms for therapeutic and diagnostic oligonucleotide delivery | — |
| 8 | OvalMedical Manufacturer of customizable autoinjector devices and contract development and manufacturing services | $8M | 136 mo ago | 25 | Ajay Singhvi Owner | — | — | — | — |
| 9 | Arecor Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery | $8M | 24 mo ago | 34 34 → 35 (+3%) | — | WordPressApple iCloud MailMicrosoft 365+21 | Top 10M | 288 patents Insulin delivery devices and pharmaceutical/biologic formulation technologies | — |
| 10 | NanoMedex Developing Nanotechnology of Microemulsions. | $8M | 178 mo ago | — | David Cooper President and CEO | — | — | — | — |
| 11 | Calla Lily Clinical Care Developer of a platform for improved vaginal drug delivery systems | $6M | 19 mo ago | 1 | Thang Vo-Ta Co-Founder & CEO | PHPVarnishPriority Hints+10 | Top 50M | — | 2 internships |
| 12 | Stable Pharma Developer of technology to store and deliver stable drugs and vaccines | $5M | 58 mo ago | 1 | — | WordPressMySQLPHP+24 | Top 50M | — | 1 launch · 3 partnerships |
| 13 | Somaserve Developer of cell imaging and bio nanoparticles | $3M | 65 mo ago | 5 | Francesca Crawford CEO | — | — | — | — |
| 14 | Nuformix Developer of drugs for the treatment of fibrosis and oncology | $2M | 39 mo ago | 4 | Stephen Cash Co-Founder | — | — | 48 patents Pharmaceutical cocrystal and salt forms of active drug molecules | — |
| 15 | LIFNano Therapeutics Nanoengineering platform to deliver Leukaemia Inhibitory Factor (LIF) | $2M | 145 mo ago | 2 | Su Metcalfe Founder | — | — | — | — |
| 16 | Atocap Manufacturer of microencapsulated drugs | $1M | 5 mo ago | 5 | Heather King CEO | — | — | — | — |
| 17 | Micropore CDMO focused on providing drug formulations manufacturing services | $1M | 79 mo ago | 13 | — | SanityFirebaseEmotion+16 | Top 50M | 9 patents Microporous membrane-based microfluidic devices for high‑shear phase dispersion and emulsification | — |
| 18 | SporeGen Provides vaccine delivery agents, probiotic foods, contract probiotic research services and reagents… | $1M | 139 mo ago | 6 | Simon Cutting CEO | — | — | 20 patents Engineered bacterial spores for targeted antimicrobial and antiviral drug delivery. | — |
| 19 | Active Needle Developer of medical devices for ultrasound-guided interventional procedures | $1M | 57 mo ago | 2 | Ian Quirk CEO and Founder | — | — | 36 patents Provides advanced tattoo and medical injection devices with precision needle cartridges. | — |
| 20 | Alchemy Pharmatech Develops drug delivery platforms with focus in non-invasive intranasal delivery | $861K | 135 mo ago | 2 | Robert Clayborough CEO | — | — | 6 patents Advanced drug delivery devices such as syringes and inhalers for precise medicament administration | — |
| 21 | VisusNano Developer of drug-eluting intraocular lens implants | $377K | 51 mo ago | 4 | — | — | — | 11 patents Drug‑eluting intraocular lens coatings and microsphere drug‑release systems for ocular therapy | — |
| 22 | C-Major Medical Developer of injury-free syringes and blood-collection systems | $275K | 69 mo ago | 6 | — | WordPressMySQLPHP+20 | Top 50M | — | — |
Top 12 Drug Delivery companies in England
#1
Seed · London, England · founded 2011 · 5 employees$1.3Mraised▾
Developer of a microencapsulation technology designed to deliver generic antibiotics for urinary tract infection with chemotherapeutics into a multi-layered capsule. The company's technology fabricates encapsulated products for controlled drug delivery for immunocompromised patients, pregnant women, and multiple sclerosis patients who are at a high risk of contracting UTI, enabling healthcare organizations to prepare a wide range of encapsulated structured drugs via a clean, efficient, one-step route.
- Feb 2026Seed$323.2K
- Nov 2020Seed$993.3K
- Oct 2020Seed$586.5K
- Feb 2017Seed$378.1K
#2
Series A · Coventry, England · founded 2018 · 3 employees$21.6Mraised▾
Developer of targeted intracellular delivery platform for biological molecules. The company focuses on enabling targeted, intracellular delivery of protein therapeutics. It creates a novel solution to the intracellular bioavailability problem. The company’s platform aims to unlock therapeutic opportunities within cells that are currently difficult to drug.
- Sep 2024Series A$13.1M
- Jul 2021Seed$8.5M
- Sep 2020Grant (prize money)—
- Sep 2020Seed—
#3
Seed · London, England · founded 2021 · 1 employees$5.7Mraised▾
Developer of a platform for improved vaginal drug delivery systems. The platform aims to address the limitations of current vaginal drug delivery methods. It focuses on improving dosage confidence and user convenience. The technology is under development and has not yet been approved for sale. The content provides general information about these products, their field of application and intended use. Their function, performance and specification are subject to further development and may deviate from those shown.
- Dec 2024Seed$3M
- Dec 2023Seed$1.6M
- Dec 2022Seed$492.3K
- Oct 2022Seed$574.6K
#4
Public · Cambridge, England · founded 2007 · 34 employees$8Mraised▾
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery. It has developed Arestat, a smart stabilization technology, which enables the formulation of labile proteins and vaccines as stable aqueous or dry preparations even at high concentrations or in the presence of ionizing radiation. As a simple reformulation, the technology can be integrated into existing manufacturing processes. Arestat does not involve the covalent modification of biologics and uses only GRAS (Generally Regarded As Safe) excipients approved by relevant regulatory authorities.
- Jul 2024Post IPO$8.3M
- Mar 2021Grant (prize money)$3.8M
- Sep 2018Series A$7.7M
- Jun 2018Grant (prize money)$1.3M
#5
Series A · Cambridge, England · founded 2018$25Mraised▾
Developer of targeted nanomedicines for drug delivery. The company utilizes proprietary technology "polyNaut" that can be formulated to encapsulate a wide array of genetic cargoes for viral and non-viral delivery for CNS diseases and cystic fibrosis.
- Nov 2023Series A$25M
#6
Public · Abingdon, England · founded 2000 · 40 employees$16Mraised▾
Provider of novel drug delivery technologies for the treatment of diseases. It develops a pipeline of product candidates in clinical and pre-clinical development for diseases such as diabetes, rare cancers including brain, ovarian, liver, and pancreatic cancer, and neurological/ophthalmologic conditions. It provides in-house technology platforms for sustained release to prolong and control the release of therapeutics over an extended period of time and dissolve insoluble drugs which can be converted into liquid form and can be treated for tumor patients.
- Feb 2023Post IPO$6M
- Aug 2020Post IPO$1M
- 2020Grant (prize money)$56.1K
- Oct 2019Post IPO$3M
#7
Series A · Coventry, England · founded 2015 · 18 employees$13.5Mraised▾
Medherant, a spin-out from the University of Warwick, manufactures transdermal drug delivery patches. They have manufactured, TEPI Patch, a higher-dosage drug delivery patch with a constant rate of drug release. Under their TEPI Patch technology, they offer Ibuprofen Patch and Methyl Salicylate Patch
- Apr 2023Series A$3.7M
- May 2019Series A$2.5M
- Dec 2017Series A$4.5M
- Sep 2016Seed$1.9M
#8
Acquired · Oxford, England · founded 2014 · 6 employees$57.5Mraised▾
Developer of drug delivery platform and therapeutics for ophthalmology. The leading programs, OXU-001 and OXU-003 enable the targeted delivery of drugs to posterior ocular tissues. The Oxusphere is a drug-containing biodegradable polymer system and Oxulumis is a semi-automated ocular administration device. The company is exploring indications in ophthalmic diseases, such as age-related macular degeneration, diabetic macular edema, and a few rare ophthalmic disorders.
- Mar 2021Series B$37M
- Jul 2016Series A$20.5M
#9
Series B · Alderley Edge, England · founded 2011 · 15 employees$23.8Mraised▾
Blueberry Therapeutics is a modern drug discovery and development company specializing in polymer-drug delivery. Its nanopolymer drug delivery system self-assembles with both small and large molecules (e.g. proteins, peptides, and nucleic acids) and “packages” them into nanoparticles. These nanoparticles enhance cellular delivery into both mammalian and bacterial cells. It is developing OTC products to treat Onychomycosis (fungal nail infection), tinea pedis (athlete’s foot), acne, and acute wounds. Also developing prescription peptide therapeutics to treat Atopic Dermatitis, Inflammatory Bowel Disease.
- Jun 2021Conventional Debt$1.1M
- Jan 2021Series B$4.9M
- Aug 2018Series B$12.8M
- May 2016Series A$4.4M
#10
Seed · London, England · founded 2017 · 16 employees$10.5Mraised▾
Developer of oligonucleotide delivery systems. The Mergo® platform is used to deliver gene therapy molecules exclusively to diseased cells. The platform allows to develop next-generation in vivo delivery systems for RNA therapeutics.
- Dec 2021Seed$2.2M
- Apr 2021Grant (prize money)$1M
- Feb 2021Seed$2.3M
- Jan 2021Grant (prize money)$371.8K
#11
Public · Cambridge, England · founded 2008 · 4 employees$2.3Mraised▾
Developer of drugs for the treatment of fibrosis and oncology. Its products are cocrystal forms of existing drugs, and hence the company can re-use safety data and can develop these drugs in a shorter timeframe.
- Apr 2023Post IPO$86.9K
- Mar 2021Post IPO$2.2M
#12
Series A · Bath, England · founded 2011 · 1 employees$5Mraised▾
Developer of technology to store and deliver stable drugs and vaccines. The company process allows the precise dosage to be pre-loaded into the syringe at the point of manufacture thus eliminating wastage, reducing costs, and ensuring a correct dose is delivered to every patient. As the vaccine is stored in a stable state it is not temperature sensitive so this removes the necessity for refrigeration.
- Sep 2021Series A$2.8M
- Jun 2019Seed$1.5M
- Oct 2015Grant (prize money)$55K
- Sep 2015Grant (prize money)$55K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Drug Delivery coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
What England researches in drug discovery
- Genomics England18
- University of New England4
- New England Biolabs2
- Phoenix Houses of New England1
- New England College1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.